Comparing Chemotherapy, Targeted Therapy, and Immunotherapy
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The LungCancer.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Lung Cancer. American Cancer Society. Available at: https://www.cancer.org/cancer/lung-cancer.html
- Takeda, K. et. al. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Lung Cancer. 2017 Feb;104:7-15. doi: 10.1016/j.lungcan.2016.12.006. Epub 2016 Dec 12. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28213003
- Ness, N. et. al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget. 2017 Apr 18; 8(16): 26789–26801. Published online 2017 Mar 1. doi: 10.18632/oncotarget.15817. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432297/
- Centers for Medicare and Medicaid Services. FDA announces approval, CMS proposes coverage of first breakthrough-designated test to detect extensive number of cancer biomarkers. Available at: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2017-Press-releases-items/2017-11-30-2.html